Gsk (GSK) Cash from Operations Growth (1y) (2010 - 2026)
Gsk (GSK) Cash from Operations Growth (1y) (2010 - 2026) Analysis & Trends
Peer Comparison
| # |
Company |
Market Cap |
Enterprise Value |
Gross Profit (Qtr) |
Cash from Ops. Growth (1y) (Qtr) |
| 1 |
Gsk |
96,436,181.12 Bn |
96,436,176.16 Bn |
7.76 Bn |
11.07% |
| 2 |
Eli Lilly |
1,017.30 Bn |
1,012.01 Bn |
16.22 Bn |
220.11% |
| 3 |
Johnson & Johnson |
579.61 Bn |
557.55 Bn |
15.96 Bn |
-39.77% |
| 4 |
AbbVie |
402.30 Bn |
392.96 Bn |
10.78 Bn |
134.19% |
| 5 |
Merck |
294.24 Bn |
288.59 Bn |
12.09 Bn |
56.72% |
| 6 |
Amgen |
191.82 Bn |
179.78 Bn |
5.87 Bn |
57.37% |
| 7 |
Gilead Sciences |
155.93 Bn |
148.21 Bn |
5.52 Bn |
44.79% |
| 8 |
Pfizer |
149.05 Bn |
136.28 Bn |
-1.21 Bn |
11.99% |
| 9 |
Bristol Myers Squibb |
116.33 Bn |
105.88 Bn |
8.07 Bn |
-43.50% |
| 10 |
Novartis Ag |
112.59 Bn |
111.90 Bn |
- |
- |
| Date | Value |
|---|
| Mar 31, 2026 |
11.07% |
| Dec 31, 2025 |
-44.49% |
| Mar 31, 2025 |
14.72% |
| Dec 31, 2024 |
50.54% |
| Mar 31, 2024 |
309.44% |
| Dec 31, 2023 |
-17.50% |
| Mar 31, 2023 |
-89.77% |
| Dec 31, 2022 |
31.13% |
| Mar 31, 2022 |
647.32% |
| Dec 31, 2021 |
-55.52% |
| Sep 30, 2021 |
-25.11% |
| Jun 30, 2021 |
-47.31% |
| Mar 31, 2021 |
-63.10% |
| Dec 31, 2020 |
86.43% |
| Sep 28, 2020 |
52.05% |
| Jun 30, 2020 |
91.81% |
| Mar 31, 2020 |
43.31% |
| Dec 31, 2019 |
-7.85% |
| Sep 30, 2019 |
14.57% |
| Jun 30, 2019 |
-3.71% |
